How do I install the Es Cushing Treat Specific Comorbidities Lifelong skill?

Run npx skillmds@latest add dromlakhani/es-cushing-treat-specific-comorbidities-lifelong in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Es Cushing Treat Specific Comorbidities Lifelong safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Es Cushing Treat Specific Comorbidities Lifelong?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Es Cushing Treat Specific Comorbidities Lifelong free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Es Cushing Treat Specific Comorbidities Lifelong?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Es Cushing Treat Specific Comorbidities Lifelong by dromlakhani

Name: Es Cushing Treat Specific Comorbidities Lifelong
Rating: 4.5 (4 reviews)
Author: dromlakhani

Es Cushing Treat Specific Comorbidities Lifelong

This skill directs lifelong treatment of cardiovascular risk factors, osteoporosis, and psychiatric symptoms in all patients with Cushing's syndrome until biochemical resolution of hypercortisolism. Use when managing any CS patient for long‑term comorbidity control; triggers include persistent hypertension, dyslipidemia, low bone density, depression, anxiety, or cognitive changes in the setting of known or suspected CS.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Treating Specific Comorbidities Associated with Cushing's Syndrome Throughout Life Until Resolution

STEP 1 — Gather Information

Confirm diagnosis of Cushing's syndrome (elevated UFC, late‑night salivary cortisol, or dexamethasone suppression test) and assess remission status; document baseline cardiovascular risk factors (BP, lipids, smoking, diabetes), osteoporosis (DEXA T‑score, fracture history), and psychiatric symptoms (PHQ‑9, GAD‑7, cognitive screening).

STEP 2 — Rule In / Rule Out

If CS is not in remission (persistent hypercortisolism), treat comorbidities while pursuing definitive CS treatment; if CS is in remission, proceed to evaluate whether comorbidities require ongoing therapy.

STEP 3 — Classify or Stratify

Stratify each comorbidity: hypertension (stage 1/2), dyslipidemia (LDL‑C thresholds), osteoporosis (T‑score ≤‑1.0 osteopenia, ≤‑2.5 osteoporosis), psychiatric severity (PHQ‑9 ≥5 mild, ≥10 moderate, ≥15 severe).

STEP 4 — Decide

Initiate or continue guideline‑directed therapy for each abnormality (antihypertensives, statins, bone‑modifying agents, antidepressants or psychotherapy) and schedule reassessment of CS remission and comorbidity control every 3–6 months.

Clinical Guardrails / Mimics / Pitfalls

Do not discontinue comorbidity treatment solely because cortisol normalizes; undertreating osteoporosis increases fracture risk; avoid overlooking psychiatric relapse; beware of glucocorticoid excess from overtreatment of adrenal insufficiency; monitor for drug‑drug interactions when using steroidogenesis inhibitors.

Concrete Clinical Example

A 48‑year‑old woman with Cushing’s disease postsurgical remission (normal UFC) presents with BP 152/94 mmHg, LDL 130 mg/dL, lumbar T‑score ‑2.8, and PHQ‑9 12. She is started on lisinopril, atorvastatin, oral bisphosphonate plus calcium/vitamin D, and sertraline; BP, lipids, BMD, and mood are rechecked at 3‑month intervals and continued lifelong until her CS remains resolved and comorbidities normalize.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

---name: es-cushing-treat-specific-comorbidities-lifelongdescription: This skill directs lifelong treatment of cardiovascular risk factors, osteoporosis, and psychiatric symptoms in all patients with Cushing's syndrome until biochemical resolution of hypercortisolism. Use when managing any CS patient for long‑term comorbidity control; triggers include persistent hypertension, dyslipidemia, low bone density, depression, anxiety, or cognitive changes in the setting of known or suspected CS.---# Treating Specific Comorbidities Associated with Cushing's Syndrome Throughout Life Until Resolution## STEP 1 — Gather InformationConfirm diagnosis of Cushing's syndrome (elevated UFC, late‑night salivary cortisol, or dexamethasone suppression test) and assess remission status; document baseline cardiovascular risk factors (BP, lipids, smoking, diabetes), osteoporosis (DEXA T‑score, fracture history), and psychiatric symptoms (PHQ‑9, GAD‑7, cognitive screening).## STEP 2 — Rule In / Rule OutIf CS is not in remission (persistent hypercortisolism), treat comorbidities while pursuing definitive CS treatment; if CS is in remission, proceed to evaluate whether comorbidities require ongoing therapy.## STEP 3 — Classify or StratifyStratify each comorbidity: hypertension (stage 1/2), dyslipidemia (LDL‑C thresholds), osteoporosis (T‑score ≤‑1.0 osteopenia, ≤‑2.5 osteoporosis), psychiatric severity (PHQ‑9 ≥5 mild, ≥10 moderate, ≥15 severe).## STEP 4 — DecideInitiate or continue guideline‑directed therapy for each abnormality (antihypertensives, statins, bone‑modifying agents, antidepressants or psychotherapy) and schedule reassessment of CS remission and comorbidity control every 3–6 months.## Clinical Guardrails / Mimics / PitfallsDo not discontinue comorbidity treatment solely because cortisol normalizes; undertreating osteoporosis increases fracture risk; avoid overlooking psychiatric relapse; beware of glucocorticoid excess from overtreatment of adrenal insufficiency; monitor for drug‑drug interactions when using steroidogenesis inhibitors.## Concrete Clinical ExampleA 48‑year‑old woman with Cushing’s disease postsurgical remission (normal UFC) presents with BP 152/94 mmHg, LDL 130 mg/dL, lumbar T‑score ‑2.8, and PHQ‑9 12. She is started on lisinopril, atorvastatin, oral bisphosphonate plus calcium/vitamin D, and sertraline; BP, lipids, BMD, and mood are rechecked at 3‑month intervals and continued lifelong until her CS remains resolved and comorbidities normalize.**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

Frequently asked questions